1-(4-氯苯基)环戊烷甲胺 | 75180-51-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氯苯基)环戊烷甲胺
• 英文名称: (1-(4-chlorophenyl)cyclopentyl)methanamine
• 英文别名: [1-(4-chlorophenyl)cyclopentyl]methanamine
• CAS: 75180-51-7
• 化学式: C₁₂H₁₆ClN
• mdl: MFCD09417031
• 分子量: 209.719
• InChiKey: LJXNEBZTTYBJJO-UHFFFAOYSA-N

物化性质

• 沸点：
  303.9±25.0 °C(Predicted)
• 密度：
  1.115±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P321,P363,P405,P501
• 危险品运输编号：
  2735
• 危险性描述：
  H314
• 包装等级：
  III

反应信息

• 作为反应物：
  描述：

  1-(4-氯苯基)环戊烷甲胺 、 4-(三氟甲氧基)苯磺酰氯 在 三乙胺 作用下， 以 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 为溶剂， 以73%的产率得到N-((1-(4-chlorophenyl)cyclopentyl)methyl)-4-(trifluoromethoxy)benzenesulfonamide
  参考文献：
  名称：

  [EN] MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME
  [FR] MODULATEURS DE LA PROTÉINE PHOSPHATASE 2A (PP2A) ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及部分与蛋白磷酸酶2A（PP2A）的化学调节剂有关，包括式（I）的化合物。本公开的化合物在治疗、预防和/或改善癌症、糖尿病、自身免疫疾病、固体器官移植排斥、移植物抗宿主病、慢性阻塞性肺疾病（COPD）、非酒精性脂肪性肝病、腹主动脉瘤、慢性肝病、心力衰竭、神经退行性疾病和心肌肥厚方面具有用处。

  公开号：

  WO2022167866A1
• 作为产物：
  描述：

  1-(4-氯苯基)-1-环戊烷甲腈 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以89%的产率得到1-(4-氯苯基)环戊烷甲胺
  参考文献：
  名称：

  [EN] MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME
  [FR] MODULATEURS DE LA PROTÉINE PHOSPHATASE 2A (PP2A) ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本公开涉及部分与蛋白磷酸酶2A（PP2A）的化学调节剂有关，包括式（I）的化合物。本公开的化合物在治疗、预防和/或改善癌症、糖尿病、自身免疫疾病、固体器官移植排斥、移植物抗宿主病、慢性阻塞性肺疾病（COPD）、非酒精性脂肪性肝病、腹主动脉瘤、慢性肝病、心力衰竭、神经退行性疾病和心肌肥厚方面具有用处。

  公开号：

  WO2022167866A1

文献信息

• [EN] NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS<br/>[FR] NOUVEAUX PHÉNYL IMIDAZOLES ET PHÉNYL TRIAZOLES EN TANT QUE MODULATEURS DE LA GAMMA SÉCRÉTASE
  申请人：PFIZER

  公开号：WO2010100606A1

  公开（公告）日：2010-09-10

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  所述化合物及其药用可接受盐已被披露，其中所述化合物具有规范中定义的Formula (I)的结构。相应的药物组合物、治疗方法、合成方法和中间体也已被披露。
• Discovery of novel 5-hydroxy-4-pyridone-3-carboxy acids as potent inhibitors of influenza Cap-dependent endonuclease
  作者：Masayoshi Miyagawa、Toshiyuki Akiyama、Minako Mikamiyama-Iwata、Kazunari Hattori、Naoko Kurihara、Yoshiyuki Taoda、Chika Takahashi-Kageyama、Noriyuki Kurose、Hidenori Mikamiyama、Naoyuki Suzuki、Kenji Takaya、Kenji Tomita、Kenji Matsuo、Kenji Morimoto、Ryu Yoshida、Takao Shishido、Tomokazu Yoshinaga、Akihiko Sato、Makoto Kawai

  DOI：10.1016/j.bmcl.2016.08.038

  日期：2016.10

  We report the discovery of a novel series of influenza Cap-dependent EndoNuclease (CEN) inhibitors based on the 4-pyridone-carboxylic acid (PYXA) scaffold, which were found from our chelate library. Our SAR research revealed the lipophilic domain to be the key to CEN inhibition. In particular, the position between the chelate and the lipophilic domain in the derivatives was essential for enhancing

  我们报告发现了一种新型的基于4-吡啶酮-羧酸（PYXA）支架的流感帽依赖性核酸内切酶（CEN）抑制剂系列，该抑制剂是从我们的螯合物库中发现的。我们的SAR研究表明，亲脂性域是CEN抑制的关键。特别地，在衍生物中的螯合物和亲脂性结构域之间的位置对于增强效力是必不可少的。我们基于虚拟模型的研究导致2y被鉴定为有效的CEN抑制剂，IC50为5.12nM。
• Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators
  申请人：Allen Martin Patrick

  公开号：US20120053165A1

  公开（公告）日：2012-03-01

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本发明公开了具有式（I）所定义的结构的化合物及其药学上可接受的盐，同时公开了相应的制药组合物、治疗方法、合成方法和中间体。
• Discovery of the First‐in‐Class Inhibitors of Hypoxia Up‐Regulated Protein 1 (HYOU1) Suppressing Pathogenic Fibroblast Activation
  作者：Dimitra Papadopoulou、Vasiliki Mavrikaki、Filippos Charalampous、Christos Tzaferis、Martina Samiotaki、Konstantinos D. Papavasileiou、Antreas Afantitis、Niki Karagianni、Maria C. Denis、Julie Sanchez、J. Robert Lane、Zacharias Faidon Brotzakis、Georgios Skretas、Dimitris Georgiadis、Alexios N. Matralis、George Kollias

  DOI：10.1002/anie.202319157

  日期：2024.4.2

  Fibroblasts are key regulators of inflammation, fibrosis, and cancer. Targeting their activation in these complex diseases has emerged as a novel strategy to restore tissue homeostasis. Here, we present a multidisciplinary lead discovery approach to identify and optimize small molecule inhibitors of pathogenic fibroblast activation. The study encompasses medicinal chemistry, molecular phenotyping assays, chemoproteomics, bulk RNA‐sequencing analysis, target validation experiments, and chemical absorption, distribution, metabolism, excretion and toxicity (ADMET)/pharmacokinetic (PK)/in vivo evaluation. The parallel synthesis employed for the production of the new benzamide derivatives enabled us to a) pinpoint key structural elements of the scaffold that provide potent fibroblast‐deactivating effects in cells, b) discriminate atoms or groups that favor or disfavor a desirable ADMET profile, and c) identify metabolic “hot spots”. Furthermore, we report the discovery of the first‐in‐class inhibitor leads for hypoxia up‐regulated protein 1 (HYOU1), a member of the heat shock protein 70 (HSP70) family often associated with cellular stress responses, particularly under hypoxic conditions. Targeting HYOU1 may therefore represent a potentially novel strategy to modulate fibroblast activation and treat chronic inflammatory and fibrotic disorders.